 | | Vol. 9.23 – 23 June, 2021 |
| |
|
|
| Scientists isolated neutralizing antibodies against the receptor-binding domain (RBD) and the N-terminal domain (NTD) of SARS-CoV-2 spike from individuals with acute or convalescent SARS-CoV-2 or a history of SARS-CoV infection.
[Cell] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
| |
|
|
| Researchers studied the ability of monoclonal antibodies, convalescent and vaccine sera to neutralize B.1.617.1 and B.1.617.2 and complement this with structural analyses of Fab/RBD complexes and map the antigenic space of current variants.
[Cell] |
|
|
|
| Scientists showed that ACE2 nanodecoys derived from human lung spheroid cells could bind and neutralize SARS-CoV-2 and protect the host lung cells from infection.
[Nature Nanotechnology] |
|
|
|
| Using a prospective cohort, the authors assessed the seroconversion rates and anti-SARS-CoV-2 spike protein antibody titers following the first and second dose of BNT162b2 and mRNA-1273 SARS-CoV-2 vaccines in patients with cancer in US and Europe from January to April 2021.
[Cancer Cell] |
|
|
|
| To examine the ontogeny and function of MS1 cells, researchers developed a cellular model for inducing CD14+ MS1 monocytes from healthy bone marrow hematopoietic stem and progenitor cells.
[Science Translational Medicine] |
|
|
|
| Scientists investigated the capacity of modified versions of one lead miniprotein, LCB1, to protect against SARS-CoV-2-mediated lung disease in mice.
[Cell Host & Microbe] |
|
|
|
| Investigators demonstrated that protein kinase R–like endoplasmic reticulum kinase (PERK) signaling mediated the proapoptotic signals in Middle East respiratory syndrome coronavirus (MERS-CoV) infection, which converged in the intrinsic apoptosis pathway.
[Science Advances] |
|
|
|
| The authors longitudinally profiled the early humoral immune response against SARS-CoV-2 in hospitalized COVID-19 patients and quantify levels of pre-existing immunity to OC43, HKU1 and 229E seasonal coronaviruses.
[Nature Communications] |
|
|
|
| In a screen for new models of SARS-CoV-2 infection, researchers identified human H522 lung adenocarcinoma cells as naturally permissive to SARS-CoV-2 infection despite complete absence of ACE2 expression.
[Cell Reports] |
|
|
|
| MORE IMMUNOLOGY OF INFECTIOUS DISEASE |
|
|
|
| Investigators showed that the skin microbiota promoted the discrete expression of defined endogenous retroviruses.
[Cell] |
|
|
|
| Researchers reported on an inhibitor of HSV helicase-primase with potent in vitro anti-herpes activity, a different mechanism of action, a low frequency of HSV resistance, and a favorable pharmacokinetic and safety profile.
[Science Translational Medicine] |
|
|
|
| Scientists reported that Vpr counteracted lysosomal-associated transmembrane protein 5 (LAPTM5), a potent inhibitor of HIV-1 particle infectivity, to enhance HIV-1 infection in macrophages.
[Nature Communications] |
|
|
|
| The authors described common genetic and structural features of protective human antibodies from several individuals recognizing the trimer interface of the influenza A hemagglutinin head, a recently identified site of vulnerability.
[Journal of Clinical Investigation] |
|
|
|
| Researchers systematically interrogated selective advantages that carrying 18 tRNAs may convey to a T4-like Vibriophage. Host DNA and RNA degraded upon infection, including host tRNAs, which were replaced by those of the phage.
[Cell Systems] |
|
|
|
| Scientists developed a chemically defined approach to RSV vaccine design, that allowed control of both immunogenicity and safety features of the vaccine
[npj Vaccines] |
|
|
|
|
| The authors made a comprehensive review on the outcomes resulted from the combination of CAR T-cell immunotherapy and oncolytic virotherapy for the treatment of solid cancers.
[Cancer Gene Therapy] |
|
|
|
| The similar role of DAMPs is addressed, that is, of those molecules, which operate upstream of the inflammatory pathway by activating those cells, which ultimately release the cytokines.
[Genes & Immunity] |
|
|
|
|
| ViiV Healthcare and Halozyme Therapeutics, Inc. announced a global collaboration and license agreement that gives exclusive access to Halozyme’s ENHANZE® drug delivery technology, recombinant human hyaluronidase PH20 enzyme, for specific targets used in the treatment and prevention of HIV.
[ViiV Healthcare (BusinessWire, Inc.)] |
|
|
|
| Vaxxinity announced a purchase order for its COVID-19 vaccine, UB-612, with the Government of Paraguay, contingent upon issuance of an Emergency Use Authorization (EUA) by the Taiwanese Food and Drug Administration, which will trigger an EUA in Paraguay.
[Vaxxinity (BusinessWire, Inc.)] |
|
|
|
|
| July 27 – 29, 2021
Virtual |
|
|
|
|
|
| | University of Gothenburg – Gothenburg, Sweden |
|
|
|
| Brigham and Women’s Hospital – Boston, Massachusetts, United States |
|
|
|
| | University of Washington – Seattle, Washington, United States |
|
|
|
| | Salk Institute – La Jolla, California, United States |
|
|
|
| | Rochester Regional Health – Rochester, New York, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
